Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387208064> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4387208064 endingPage "e9" @default.
- W4387208064 startingPage "e9" @default.
- W4387208064 abstract "For patients with locally recurrent thoracic tumors or second primaries within previously irradiated volumes, hyperfractionated reirradiation (re-RT) may mitigate late toxicity compared to conventional fractionation, but clinical outcomes have not been extensively studied. We herein report our institutional experience with thoracic hyperfractionated reirradiation.We identified 26 cases among 23 patients treated with re-RT to either primary or metastatic thoracic tumors, 60 Gy in 50 fractions, twice daily over 5 weeks using highly conformal image guided RT with motion management. Nineteen patients had dosimetry data available. The primary outcome was Grade (G2) or higher toxicity rates per CTCAEv5.0. Secondary endpoints were 12-month local control (LC), progression free survival (PFS)-determined by treating physician and/or multidisciplinary tumor board-and overall survival (OS).Median follow-up was 13 months. Half had non-small cell lung cancer, 95.8% had ultracentral tumors, 57.7% had single prior thoracic RT course; 38.5%, 11.5% and 11.5% received concurrent chemotherapy, immunotherapy, and targeted agents, respectively. Minimum and median intervals between RT courses were 10 and 39.5 months, respectively; 94.7% of re-irradiation plans had overlapping 80% isodose volumes. Median OS and PFS were 13 and 10 months, respectively. Crude 12-month LC was 73.1%. Of those with a recurrence, the first recurrence occurred locally in 6 (54.6%), regionally in 3 (27.3%), and distantly in 8 (72.7%) patients. ≥G2 and ≥G3 toxicity rates were 30.8% and 7.69%, respectively (one G3 atrial fibrillation; one G5 pneumonitis). Using the American Radium Society guidelines for thoracic reirradiation, only 10.5% met all dose volume constraint recommendations.Definitive hyperfractionated thoracic re-RT was well tolerated with promising local control. ≥G3 toxicities were rare. Patients should be counseled on the low but potential risk of life-threatening toxicity. Consensus guidelines for dose constraints may be difficult to meet in reirradiation setting; in this cohort, rates of severe toxicity were low despite exceeding putative constraints in most patients." @default.
- W4387208064 created "2023-09-30" @default.
- W4387208064 creator A5001077235 @default.
- W4387208064 creator A5001873561 @default.
- W4387208064 creator A5002961787 @default.
- W4387208064 creator A5003025241 @default.
- W4387208064 creator A5016420174 @default.
- W4387208064 creator A5027545520 @default.
- W4387208064 creator A5035374661 @default.
- W4387208064 creator A5038994179 @default.
- W4387208064 creator A5088372825 @default.
- W4387208064 date "2023-10-01" @default.
- W4387208064 modified "2023-10-14" @default.
- W4387208064 title "Hyperfractionated Reirradiation for Locally Recurrent Thoracic Tumors" @default.
- W4387208064 doi "https://doi.org/10.1016/j.ijrobp.2023.06.666" @default.
- W4387208064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37786208" @default.
- W4387208064 hasPublicationYear "2023" @default.
- W4387208064 type Work @default.
- W4387208064 citedByCount "0" @default.
- W4387208064 crossrefType "journal-article" @default.
- W4387208064 hasAuthorship W4387208064A5001077235 @default.
- W4387208064 hasAuthorship W4387208064A5001873561 @default.
- W4387208064 hasAuthorship W4387208064A5002961787 @default.
- W4387208064 hasAuthorship W4387208064A5003025241 @default.
- W4387208064 hasAuthorship W4387208064A5016420174 @default.
- W4387208064 hasAuthorship W4387208064A5027545520 @default.
- W4387208064 hasAuthorship W4387208064A5035374661 @default.
- W4387208064 hasAuthorship W4387208064A5038994179 @default.
- W4387208064 hasAuthorship W4387208064A5088372825 @default.
- W4387208064 hasBestOaLocation W43872080641 @default.
- W4387208064 hasConcept C126322002 @default.
- W4387208064 hasConcept C126838900 @default.
- W4387208064 hasConcept C143998085 @default.
- W4387208064 hasConcept C155806632 @default.
- W4387208064 hasConcept C2777714996 @default.
- W4387208064 hasConcept C2779524853 @default.
- W4387208064 hasConcept C2908786992 @default.
- W4387208064 hasConcept C29730261 @default.
- W4387208064 hasConcept C2989005 @default.
- W4387208064 hasConcept C509974204 @default.
- W4387208064 hasConcept C71924100 @default.
- W4387208064 hasConceptScore W4387208064C126322002 @default.
- W4387208064 hasConceptScore W4387208064C126838900 @default.
- W4387208064 hasConceptScore W4387208064C143998085 @default.
- W4387208064 hasConceptScore W4387208064C155806632 @default.
- W4387208064 hasConceptScore W4387208064C2777714996 @default.
- W4387208064 hasConceptScore W4387208064C2779524853 @default.
- W4387208064 hasConceptScore W4387208064C2908786992 @default.
- W4387208064 hasConceptScore W4387208064C29730261 @default.
- W4387208064 hasConceptScore W4387208064C2989005 @default.
- W4387208064 hasConceptScore W4387208064C509974204 @default.
- W4387208064 hasConceptScore W4387208064C71924100 @default.
- W4387208064 hasIssue "2" @default.
- W4387208064 hasLocation W43872080641 @default.
- W4387208064 hasLocation W43872080642 @default.
- W4387208064 hasOpenAccess W4387208064 @default.
- W4387208064 hasPrimaryLocation W43872080641 @default.
- W4387208064 hasRelatedWork W114545845 @default.
- W4387208064 hasRelatedWork W1973870257 @default.
- W4387208064 hasRelatedWork W1975164313 @default.
- W4387208064 hasRelatedWork W1982848321 @default.
- W4387208064 hasRelatedWork W2013237588 @default.
- W4387208064 hasRelatedWork W2051409818 @default.
- W4387208064 hasRelatedWork W2096163540 @default.
- W4387208064 hasRelatedWork W2147617362 @default.
- W4387208064 hasRelatedWork W2356268906 @default.
- W4387208064 hasRelatedWork W2404466019 @default.
- W4387208064 hasVolume "117" @default.
- W4387208064 isParatext "false" @default.
- W4387208064 isRetracted "false" @default.
- W4387208064 workType "article" @default.